Infographic | The leaders of the global hepatitis-C market
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Hepatitis C
Five things for pharma marketers to know: Friday, August 4, 2017
AbbVie’s new HCV drug is cheaper than Gilead’s Harvoni; Lilly’s experimental migraine drugs beats placebo; Fitbit to launch smartwatch
Gilead’s educational campaign boosted HCV diagnosis rates for baby boomers
An unbranded campaign encouraging baby boomers to get tested for hepatitis C helped boost screening and diagnosis numbers, which in turn upped sales of its HCV therapies.
Five things for pharma marketers to know: Monday, July 24, 2017
Samsung Bioepis launches Remicade biosimilar; WHO encourages uses of generic version of Sovaldi; nearly 20 million people with HIV on treatment
Five things for pharma marketers to know: Monday, April 10, 2017
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Five things for pharma marketers to know: Wednesday, March 29, 2017
A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year
Five things for pharma marketers to know: Tuesday, March 14, 2017
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Five things for pharma marketers to know: Thursday, December 29, 2016
Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products
Gilead’s Meyers on making deals and finding unmet patient needs
The drugmaker’s new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.
Five things for pharma marketers to know: Wednesday, October 5, 2016
The FDA to require black-box warnings for hep.-C drugs; AstraZeneca’s Brilinta fails to meet study goals; ICER says PD-1s are too pricey
